| Abstract: | An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period. |
|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,871,241
U.S. Patent 8,871,241, titled "Compositions and Methods for Disease Treatment," was granted to Amgen Inc. on October 28, 2014. The patent covers specific monoclonal antibodies targeting PCSK9, a protein that modulates LDL cholesterol levels, with implications for hypercholesterolemia and cardiovascular disease treatment.
Scope of the Patent
The patent claims encompass novel monoclonal antibodies, their antigen-binding fragments, and methods for their use. The key features include:
-
Antigen specificity: Antibodies specifically bind to human PCSK9, inhibiting its interaction with LDL receptors.
-
Binding affinity: Claims specify binding affinities typically below 1 nanomolar, ensuring high potency.
-
Sequence limitations: Several claims define heavy and light chain variable regions with specific sequences, including certain CDR (complementarity-determining region) amino acid compositions.
-
Antibody formats: Claims include intact IgG molecules and antigen-binding fragments such as Fab and scFv.
-
Methods of use: Therapeutic methods involve administering effective doses of these antibodies to treat hypercholesterolemia or related cardiovascular conditions.
-
Manufacturing and formulation: Claims also cover methods of manufacturing and pharmaceutical formulations for stability and bioavailability.
Claims Breakdown
The patent includes multiple independent claims, primarily:
-
Monoclonal antibodies binding human PCSK9 with specific CDR sequences. These define particular amino acid sequences and binding characteristics.
-
Antibody fragments with equivalent binding properties. These include Fab, scFv, or other antigen-binding fragments.
-
Methods of inhibiting PCSK9 activity and reducing LDL cholesterol levels. These involve administering the antibodies described.
-
Methods for manufacturing the antibodies. Covering expression systems and purification processes.
Claims are detailed with sequence identity thresholds, often requiring at least 85-95% identity to the disclosed sequences, allowing for some variation while maintaining binding properties.
Patent Landscape Analysis
The patent landscape around anti-PCSK9 antibodies is competitive and rapidly evolving. Key aspects include:
-
Major Players: Amgen (developing evolocumab, marketed as Repatha), Regeneron and Sanofi (developing alirocumab, marketed as Praluent), and numerous biotech companies holding different patents around PCSK9 antagonism.
-
Patent Families and Terminal Dispensations: Amgen's patent family related to 8,871,241 extends the scope for anti-PCSK9 antibodies, with related patents covering specific sequences, methods, and formulations.
-
Expiration Timeline: The patent’s earliest priority date is 2007. If maintained, the patent would generally expire 20 years from the earliest filing date (likely around 2027-2028), though extensions or pediatric exclusivities could affect exclusivity periods.
-
Blocking and Obviousness Challenges: Several patents and applications are still pending or issued, focusing on alternative antibody sequences, bispecifics, or small-molecule inhibitors, creating a dense patent thicket.
-
Litigation Risks: Amgen’s patent has been involved in legal disputes with other companies over PCSK9 inhibitors, including patent validity and infringement issues that impact freedom-to-operate.
Recent Patent Applications and Trends
Implications for Development and Commercialization
-
The patent provides robust protection for specific monoclonal antibodies against PCSK9, enabling Amgen or licensees to commercialize these molecules exclusively until expiration.
-
The broad claims covering antibody fragments allow for manufacturing flexibility.
-
The landscape suggests ongoing innovation to circumvent existing patents, including new sequences or delivery systems.
Key Takeaways
-
U.S. Patent 8,871,241 claims specific monoclonal antibodies binding human PCSK9, with defined sequences and binding properties.
-
The patent supports therapeutic use in hypercholesterolemia, contributing to the IP position of Amgen’s PCSK9 inhibitors.
-
The patent landscape is crowded, with ongoing patent filings, legal disputes, and efforts to carve out novel antibody formats or alternative modalities.
-
Expiration is likely around 2027–2028, but patent extension strategies may alter the timeline.
-
Innovation continues around optimizing antibody efficacy, pharmacokinetics, and delivery, indicating a dynamic competition environment.
FAQs
-
What distinguishes the claims of U.S. Patent 8,871,241 from other PCSK9 antibody patents?
It claims specific antibody sequences with defined binding affinities, focusing on particular CDR regions, whereas other patents may claim different sequences or formats.
-
Are there any legal challenges to this patent?
While specific litigations are not publicly documented for this patent, Amgen’s broader PCSK9 patent portfolio has faced litigation risks, especially concerning similar antibody sequences.
-
Can biosimilar developers design around this patent?
Yes, by developing antibodies with significantly different sequences or binding properties, but such approaches require careful analysis of claim language and patent scope.
-
What is the expiry date of this patent?
The patent is likely set to expire around 2027–2028, based on its filing timeline, unless extended.
-
How does the patent landscape impact future innovation?
The dense patent environment encourages innovation in antibody engineering, alternative modalities, and improved formulations to maintain competitive advantage.
References
- U.S. Patent No. 8,871,241.
- FDA Drug Approvals Database.
- Patent Office filings and legal case summaries.
- Industry reports on PCSK9 inhibitors.
- Amgen’s patent portfolio and related literature.
More… ↓
⤷ Start Trial
|
